144 related articles for article (PubMed ID: 11042872)
1. [Substance P receptor antagonists--a new antidepressive and anxiolytic mechanism?].
Lieb K; Fiebich BL; Berger M
Nervenarzt; 2000 Sep; 71(9):758-61. PubMed ID: 11042872
[TBL] [Abstract][Full Text] [Related]
2. Reward for persistence in substance P research.
Wahlestedt C
Science; 1998 Sep; 281(5383):1624-5. PubMed ID: 9767028
[No Abstract] [Full Text] [Related]
3. Distinct mechanism for antidepressant activity by blockade of central substance P receptors.
Kramer MS; Cutler N; Feighner J; Shrivastava R; Carman J; Sramek JJ; Reines SA; Liu G; Snavely D; Wyatt-Knowles E; Hale JJ; Mills SG; MacCoss M; Swain CJ; Harrison T; Hill RG; Hefti F; Scolnick EM; Cascieri MA; Chicchi GG; Sadowski S; Williams AR; Hewson L; Smith D; Carlson EJ; Hargreaves RJ; Rupniak NM
Science; 1998 Sep; 281(5383):1640-5. PubMed ID: 9733503
[TBL] [Abstract][Full Text] [Related]
4. Substance-P antagonists: a new treatment for depression?
Nutt D
Lancet; 1998 Nov; 352(9141):1644-6. PubMed ID: 9853433
[No Abstract] [Full Text] [Related]
5. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with substance P receptor (NK1) antagonists in depression.
Ranga K; Krishnan R
J Clin Psychiatry; 2002; 63 Suppl 11():25-9. PubMed ID: 12562140
[TBL] [Abstract][Full Text] [Related]
7. Substance P: a new era, a new role.
DeVane CL
Pharmacotherapy; 2001 Sep; 21(9):1061-9. PubMed ID: 11560196
[TBL] [Abstract][Full Text] [Related]
8. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.
Keller M; Montgomery S; Ball W; Morrison M; Snavely D; Liu G; Hargreaves R; Hietala J; Lines C; Beebe K; Reines S
Biol Psychiatry; 2006 Feb; 59(3):216-23. PubMed ID: 16248986
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist.
Ballard TM; Sänger S; Higgins GA
Eur J Pharmacol; 2001 Feb; 412(3):255-64. PubMed ID: 11166289
[TBL] [Abstract][Full Text] [Related]
10. Aprepitant: a novel neurokinin-1 receptor/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma.
Ladizinski B; Bazakas A; Olsen EA
J Am Acad Dermatol; 2012 Nov; 67(5):e198-9. PubMed ID: 23062910
[No Abstract] [Full Text] [Related]
11. Aprepitant--a novel NK1-receptor antagonist.
Patel L; Lindley C
Expert Opin Pharmacother; 2003 Dec; 4(12):2279-96. PubMed ID: 14640927
[TBL] [Abstract][Full Text] [Related]
12. Substance P antagonists: meet the new drugs, same as the old drugs? Insights from transgenic animal models.
Santarelli L; Saxe MD
CNS Spectr; 2003 Aug; 8(8):589-96. PubMed ID: 12907922
[TBL] [Abstract][Full Text] [Related]
13. Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus.
Maubach KA; Martin K; Chicchi G; Harrison T; Wheeldon A; Swain CJ; Cumberbatch MJ; Rupniak NM; Seabrook GR
Neuroscience; 2002; 109(3):609-17. PubMed ID: 11823070
[TBL] [Abstract][Full Text] [Related]
14. The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists.
Varty GB; Cohen-Williams ME; Morgan CA; Pylak U; Duffy RA; Lachowicz JE; Carey GJ; Coffin VL
Neuropsychopharmacology; 2002 Sep; 27(3):371-9. PubMed ID: 12225694
[TBL] [Abstract][Full Text] [Related]
15. [Substance P-antagonists as a new class of antidepressant drugs].
Lieb K; Herpfer I; Fiebich BL; Berger M
Dtsch Med Wochenschr; 2002 Nov; 127(48):2563-5. PubMed ID: 12457326
[No Abstract] [Full Text] [Related]
16. Substance P antagonists: the next breakthrough in treating depression?
Baby S; Nguyen M; Tran D; Raffa RB
J Clin Pharm Ther; 1999 Dec; 24(6):461-9. PubMed ID: 10651979
[TBL] [Abstract][Full Text] [Related]
17. Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Hafizi S; Chandra P; Cowen J
Br J Psychiatry; 2007 Oct; 191():282-4. PubMed ID: 17906236
[TBL] [Abstract][Full Text] [Related]
18. Developing small molecule nonpeptidergic drugs for the treatment of anxiety disorders: is the challenge still ahead?
Steckler T
Curr Top Behav Neurosci; 2010; 2():415-28. PubMed ID: 21309119
[TBL] [Abstract][Full Text] [Related]
19. [Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
Osváth P
Neuropsychopharmacol Hung; 2013 Sep; 15(3):147-55. PubMed ID: 24108179
[TBL] [Abstract][Full Text] [Related]
20. Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response.
Blier P; Gobbi G; Haddjeri N; Santarelli L; Mathew G; Hen R
J Psychiatry Neurosci; 2004 May; 29(3):208-18. PubMed ID: 15173897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
